Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo‐refractory germ cell tumors

OBJECTIVES: Germ cell tumors are highly susceptible to chemotherapy; however, there is a lack of established treatments for consistently relapsing germ cell tumor. Therefore, in this phase II study, we evaluated the efficacy and safety of nivolumab for relapsed germ cell tumor. METHODS: Seventeen ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawahara, Takashi, Kawai, Koji, Kojima, Takahiro, Nagumo, Yoshiyuki, Sakka, Shotarou, Kandori, Shuya, Negoro, Hiromitsu, Mathis, Bryan J, Maruo, Kazushi, Miura, Koji, Sakamoto, Noriaki, Shinohara, Nobuo, Yamashita, Shinichi, Yonemori, Kan, Kishida, Takeshi, Ukimura, Osamu, Nishimura, Kazuo, Kobayashi, Yasuyuki, Nishiyama, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles: Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545636/
https://www.ncbi.nlm.nih.gov/pubmed/35462438
http://dx.doi.org/10.1111/iju.14885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545636/
https://www.ncbi.nlm.nih.gov/pubmed/35462438
http://dx.doi.org/10.1111/iju.14885

Ejemplares similares